Moderna Stock Price

last updated on

Moderna Stock Price

Moderna Stock Price Gained 550% in 2026. Is It A Buy?

Moderna (MRNA) hasn't been doing so well in the last few years. The results are not as strong as they once were, mainly due to the diminishing demand for the COVID vaccine.

However, the Moderna share price has really surged lately. One reason behind the massive upside in Moderna's stock price has to do with a cancer vaccine. Moderna is working on it with another company, Merck. This vaccine represents a massive growth opportunity for Moderna.

Moderna's share price has gone up by 550% in 2026 so far. So, is it still the right time to buy Moderna stock, or are you too late to the party? Let's look closely at Moderna.

Moderna Stock Price Is At Record Highs

The key catalyst behind the upside in Moderna's share price was a press release. The company announced positive results for the phase 3 trials related to Keytruda and intismeran autogene. The results showed meaningful improvements in cancer patients.

The treatment is significant in cases where the patients are dealing with melanoma. It is a skin cancer with a high risk of recurrence. It could be used by melanoma patients who have undergone surgery for cancer. For now, there is a good chance that Instismeran will get approval from the regulatory bodies.

All of this is the key reason why Moderna stock is doing so well as of late. The stock is doing so well that it is already trading above the average target set by analysts.

This new treatment can easily add billions in revenue to Moderna's bottom line. However, analysts think it still doesn't mean Moderna will instantly return to profitability.

As things stand right now, Moderna's stock price looks way too overpriced. So, it is better to avoid buying Moderna stock just out of FOMO. You can find other stocks in the health and pharma sector that are available at more reasonable valuations.

Trending Stories